|
Indications and Dosage
Oral
Hyperlipidaemias Adult: As tab: Initially, 2 g 1-2 times daily, increase by 2 g 1-2 times daily at 1-2 mth intervals. Maintenance: 2-16 g daily in 1 or divided doses. As granules for susp: Initially, 5 g 1-2 times daily, increased in 5-g increments at intervals of 1 mth. Max: 30 g daily in 1-2 divided doses.
|
|
Reconstitution
Mix contents of sachet to at least 100 mL of water or other suitable liquid (e.g. fruit juice, skimmed milk, non-carbonated beverage). Alternatively, it can be mixed w/ soups, cereals, pulpy fruits w/ a higher water content or yoghurt.
|
|
Special Precautions
Patient w/ GI dysfunction (e.g. constipation), phenylketonuria, limited thyroid reserve. Pregnancy and lactation.
|
|
Adverse Reactions
Constipation, faecal impaction, aggravation of haemorrhoids, abdominal discomfort (e.g. pain, cramping, distention), heartburn, flatulence, nausea, vomiting, diarrhoea, bloating, belching, indigestion, blood in stool; headache, migraine headache, sinus headache, dizziness, light-headedness, insomnia, anxiety, vertigo, drowsiness; rash, urticaria, dermatitis, muscle and joint pain, arthritis, backache, anorexia, fatigue, weakness, shortness of breath, swelling of the hands or feet; increased bleeding tendency (chronic use), hyperchloremic acidosis, transient and modest increases in serum AST, serum ALT and alkaline phosphatase concentrations.
|
|
Monitoring Parameters
Determine serum cholesterol and triglyceride concentrations prior to and regularly during therapy.
|
|
Overdosage
Symptoms: GI obstruction. Management: Dependent on the degree and location of obstruction and GI motility. Expert opinion is required.
|
|
Drug Interactions
May interfere w/ absorption of folic acid, oral phosphate supplements, and fats, preventing absorption of fat-soluble vit. Decreased absorption of tetracycline, penicillin G, hydrochlorothiazide, furosemide or gemfibrozil. May bind digoxin in the GI tract and impair its absorption. Decreased and/or delayed GI absorption of propranolol. May decrease serum concentration of mycophenolic acid.
|
|
Action
Description: Colestipol binds w/ bile acids in the intestine to form an insoluble complex which is excreted in faeces, resulting in increased faecal loss of bile acid-bound LDL cholesterol.
Pharmacokinetics: Absorption: Not absorbed. Excretion: Via faeces. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Database. Colestipol, CID=62816, https://pubchem.ncbi.nlm.nih.gov/compound/Colestipol (accessed on Jan. 22, 2020) |
|
Storage
Store between 20-25°C.
|
|
MIMS Class
|
|
References
Anon. Colestipol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/10/2014. Buckingham R (ed). Colestipol Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/10/2014. Colestid Granules and Tablets. U.S. FDA. https://www.fda.gov/. Accessed 01/10/2014. Colestid Tablet (Pharmacia and Upjohn Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/10/2014. McEvoy GK, Snow EK, Miller J et al (eds). Colestipol Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/10/2014.
|
Sign Out
